DARANIDE® (dichlorphenamide tablets USP) is an oral carbonic anhydrase inhibitor.
(dichlorphenamide tablets USP) is indicated for the treatment of elevated intraoculr pressure.
Media Articles Related to Daranide (Dichlorphenamide)
FDA Nod for Keveyis in Primary Periodic Paralysis
Source: Medscape NeurologyHeadlines [2015.08.25]
FDA has approved dichlorphenamide, the first treatment for primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause muscle weakness or paralysis.
Published Studies Related to Daranide (Dichlorphenamide)
Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. [2000.01]
Although the carbonic anhydrase inhibitors have been used in the treatment of the primary periodic paralyses (PPs), their efficacy has not been demonstrated in double-blind, placebo-controlled trials. Therefore, we tested the efficacy of dichlorphenamide (DCP; Daranide), a potent carbonic anhydrase inhibitor, in the treatment of episodic weakness in the primary PPs...
Clinical Trials Related to Daranide (Dichlorphenamide)
Hyper- and Hypokalemic Periodic Paralysis Study [Completed]
The purpose of this study is to compare Dichlorphenamide with placebo (an inactive
substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP)
and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term
effects of Dichlorphenamide in periodic paralysis.
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders [Completed]
I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in
patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic
paralysis, and hypokalemic periodic paralysis.
Page last updated: 2015-08-25